Callisto Pharmaceuticals Inc.
15.01.2013 11:00
---------------------------------------------------------------------------
NEW YORK, 2013-01-15 11:00 CET (GLOBE NEWSWIRE) --
Callisto Pharmaceuticals, Inc. (OTCQB:CLSP) ('Callisto') today announced that
it convened its special meeting of stockholders yesterday and it has received
the necessary approvals from its stockholders to authorize Callisto's merger
with and into Synergy Pharmaceuticals Inc. ('Synergy') pursuant to the
previously announced Agreement and Plan of Merger, dated July 20, 2012, as
amended on October 15, 2012. Callisto and Synergy expect to close the merger as
soon as practicable.
About Callisto Pharmaceuticals Inc.
Callisto is a development stage biopharmaceutical company. All of Callisto's
drug candidates, currently plecanatide and SP-333 to treat GI disorders and
diseases, are being developed exclusively by Synergy.
CONTACT: Investor Contact:
Danielle Spangler
The Trout Group
synergy@troutgroup.com
(646) 378-2924
News Source: NASDAQ OMX
15.01.2013 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Callisto Pharmaceuticals Inc.
United States
Phone:
Fax:
E-mail:
Internet:
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
DGAP-News: Callisto Stockholders Approve Merger With Synergy Pharmaceuticals
| Source: EQS Group AG